Domov › Burkitov lymfóm › Georgia
Klinické štúdie Burkitov lymfóm v štáte Georgia
12 štúdií pre Burkitov lymfóm hľadá účastníkov v zariadeniach v štáte Georgia.
Mestá v štáte Georgia
Oficiálny text štúdie (anglicky)
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
- Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta
- Augusta University Medical Center, Augusta
- Atrium Health Navicent, Macon
- a 1 ďalších
Prebieha náborFáza 2
366 Days – 46 Years · Všetky pohlavia · Aktualizované 2. 10. 2026 · NCT06124157Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
- Emory University Hospital/Winship Cancer Institute, Atlanta
- Augusta University Medical Center, Augusta
Prebieha náborFáza 3
Vek 18 až 39 · Všetky pohlavia · Aktualizované 2. 10. 2026 · NCT03150693Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
- Children's Healthcare of Atlanta - Arthur M. Blank Hospital, Atlanta
Prebieha náborObservačná štúdia
Vek 0 až 38 · Všetky pohlavia · Aktualizované 1. 10. 2026 · NCT06131801Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
- Emory University Hospital/Winship Cancer Institute, Atlanta
- Emory Saint Joseph's Hospital, Atlanta
Prebieha náborFáza 2
Vek 18 a viac · Všetky pohlavia · Aktualizované 29. 9. 2026 · NCT03739814Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
- Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta
Prebieha náborFáza 2
365 Days · Všetky pohlavia · Aktualizované 25. 9. 2026 · NCT06317662Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
- Winship Cancer Institute Emory University, Atlanta
- Northside Hospital Cancer Institute, Atlanta
Prebieha náborFáza 1
Vek 18 a viac · Všetky pohlavia · Aktualizované 8. 9. 2026 · NCT03666000A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
- Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta
- Memorial Health University Medical Center, Savannah
Prebieha náborFáza 2
Vek 1 až 30 · Všetky pohlavia · Aktualizované 1. 9. 2026 · NCT04546399Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
- Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta
- Augusta University Medical Center, Augusta
- Atrium Health Navicent, Macon
- a 1 ďalších
Prebieha náborFáza 3
365 Days – 25 Years · Všetky pohlavia · Aktualizované 25. 8. 2026 · NCT03959085Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
- Children's Healthcare of Atlanta at Egleston, Atlanta
Prebieha náborFáza 2
Vek 7 až 25 · Všetky pohlavia · Aktualizované 19. 8. 2026 · NCT05082519AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
- Research Site, Atlanta
Prebieha náborFáza 1/2
Vek 12 a viac · Všetky pohlavia · Aktualizované 19. 8. 2026 · NCT06137118Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
- Winship Cancer Institute, Emory University, Atlanta
- Augusta Cancer Center, Augusta
Prebieha náborFáza 1
Vek 18 a viac · Všetky pohlavia · Aktualizované 5. 11. 2025 · NCT04260022The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL
- Children's Healthcare of Atlanta, Atlanta
Prebieha náborFáza 2
Vek 1 až 25 · Všetky pohlavia · Aktualizované 4. 5. 2025 · NCT03509961Z ClinicalTrials.gov, dáta načítané 5. 10. 2026. Každá štúdia má vlastné kritériá oprávnenosti; tím štúdie rozhoduje o účasti.